● Recruiting

A Phase I Study of Hyper-CVAD In Combination With Venetoclax In Pediatric Patients With Relapsed or Refractory Acute Leukemias That Are of the Lymphoid Lineage Including Bi-Phenotypic or Undifferentiated Leukemias

Condition: Refractory Acute Leukemia · Relapsed Acute Leukemia · Undifferentiated Leukemia · Sponsor: M.D. Anderson Cancer Center

PhasePhase 1

Planned participants22

Who can joinAll sexes, 2 Years to 21 Years

Healthy volunteersNo

About this study

To find the recommended dose of hyper-CVAD in combination with venetoclax that can be given to participants with relapsed or refractory leukemia.

This description comes directly from the study's public registry record.

Talk to the study team

David McCall, MD · (713) 792-6604 · dmccall1@mdanderson.org

Always discuss trial participation with your own doctor first.

Locations (1)

MD Anderson Cancer Center

Houston, Texas, United States

Recruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT06466395